国家专利数据库的中药复方治疗胰腺癌用药规律分析

doi:10.20047/j.issn1673-7210.2023.06.02

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (2054 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the medication rule of traditional Chinese medicine compound prescription of national patent database in treating pancreatic cancer based on data mining. Methods The patent of traditional Chinese medicine compound prescription for treating pancreatic cancer from inception to May 2022 were searched by China Patent Announcement website. The prescription database was established with Excel software. The ancient and modern medical case cloud platform, IBM SPSS Modeler, and IBM SPSS Statistics software were used to analyze the medication rules of normalized data. Results A total of 55 traditional Chinese medicine compound prescriptions patents for the treatment of pancreatic cancer were included, including 426 Chinese herbs. Their properties were mainly cold and warm; the tastes were mainly bitter, sweet, and pungent; drugs were mainly belong to liver, spleen, and lung channel tropism. High-frequency single traditional Chinese medicines include Herba Hedyotis, Radix Glycyrrhizae, Rhizoma Atractylodis Macrocephalae, Rhizoma Corydalis, Herba Scutellariae Barbatae, Radix Angelicae Sinensis, Semen Coicis, and Radix Bupleuri, etc. High-frequency drug pairs included “Rhizoma Atractylodis Macrocephalae-Radix Glycyrrhizae” and “Herba Hedyotis-Herba Scutellariae Barbatae”, etc. The association rule analysis obtained 27 drug groups. Three core drug groups were obtained by cluster analysis of high-frequency drugs. Conclusion The treatment of pancreatic cancer with traditional Chinese medicine compound prescription has an obvious rule. In the treatment of pancreatic cancer, the formula can be combined with cold and warm drugs, and harmonize the liver and spleen. The basic treatment is strengthening and consolidating body resistance, removing toxicity and inhibiting tumor growth.

Key words： Pancreatic cancer Traditional Chinese medicine compound prescription National patent Data mining Compatibility law

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TIAN Chao1 CHENG Zixuan1 GUO Yiying2 CUI Lingjun1 TAN Huangying3

Cite this article:

TIAN Chao1 CHENG Zixuan1 GUO Yiying2 CUI Lingjun1 TAN Huangying3. Analysis of medication rule of traditional Chinese medicine compound prescription in treating pancreatic cancer based on national patent database[J]. 中国医药导报, 2023, 20(6): 9-12.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.06.02 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I6/9

[1] Tempero MA，Malafa MP，Al-Hawary M，et al. Pancreatic Adenocarcinoma，Version 2.2021，NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Canc Netw，2021， 19（4）：439-457.
[2] 王江威，苏晓琳，赵婉，等.中药治疗胰腺癌的临床应用及作用机制研究进展[J].中国医药导报，2020，17（7）：31- 34.
[3] 国家卫生健康委办公厅.胰腺癌诊疗指南（2022年版）[J].临床肝胆病杂志，2022，38（5）：1006-1015.
[4] 王馨慧，刘小英，付文胜.胰腺癌的中医药治疗研究进展[J].中国中西医结合消化杂志，2022，30（4）：303-307.
[5] 国家药典委员会.中华人民共和国药典[M].一部.北京：中国医药科技出版社，2020.
[6] 李明焱.中华本草[M].北京：中国中医药出版社，2021.
[7] 喻梅.数据分析与数据挖掘[M].北京：清华大学出版社，2020.
[8] Park W，Chawla A，O’Reilly EM. Pancreatic Cancer：A Review [J]. JAMA，2021，326（9）：851-862.
[9] Zhao C，Gao F，Li Q，et al. The Distributional Characteristic and Growing Trend of Pancreatic Cancer in China [J]. Pancreas，2019，48（3）：309-314.
[10] Hu JX，Zhao CF，Chen WB，et al. Pancreatic cancer：A review of epidemiology，trend，and risk factors [J]. World J Gastroenterol，2021，27（27）：4298-4321.
[11] 沈珊珊，李洪祯，余媛媛.中国胰腺癌高危人群早期筛查和监测共识意见（2021南京）[J].临床肝胆病杂志，2022，38（5）：1016-1022.
[12] 王馨慧，刘小英，付文胜.胰腺癌的中医药治疗研究进展[J].中国中西医结合消化杂志，2022，30（4）：303-307.
[13] 陈钧泽，齐元富.中医药治疗胰腺癌应用研究进展[J].山东中医杂志，2021，40（3）：315-318.
[14] 陈志湧.益气健脾化瘀汤辅助治疗晚期胰腺癌的临床效果[J].中国当代医药，2021，28（25）：195-197.
[15] 李梓盟，张佳彦，李菲，等.白花蛇舌草抗肿瘤化学成分及药理作用研究进展[J].中医药信息，2021，38（2）：74- 79.
[16] 王信，马传江，杨培民，等.白花蛇舌草抗炎、抗肿瘤作用研究进展[J].中国现代应用药学，2020，37（19）：2420- 2427.
[17] 王苑，王优，谭燕珍，等.白花蛇舌草提取物对白血病HL-60细胞的抑制作用[J].中国医药导报，2009，6（32）：33-34.
[18] 王自闯，张娟，陈小永.白花蛇舌草提取物通过Hippo- YAP信号通路抑制胰腺癌SW1990细胞上皮细胞间质转化[J].中国免疫学杂志，2020，36（16）：1957-1961.
[19] 连小龙，令颖，张尚龙，等.甘草有效成分抗肿瘤作用机制及联合抗肿瘤研究进展[J].中国实验方剂学杂志，2022， 28（11）：238-245.
[20] 刘丽，张旭，陈劼，等.异甘草素抑制胰腺癌SW1990细胞增殖及对survivin表达的影响[J].南京医科大学学报（自然科学版），2015，35（10）：1383-1386.
[21] 袁建晖，范燕燕，胡小青.甘草次酸对子宫内膜癌细胞增殖、凋亡、侵袭迁移的影响及机制[J].中国当代医药，2022，29（28）：9-12.
[22] 许飞，李学军.白术的抗肿瘤作用及临床应用研究进展[J].新乡医学院学报，2021，38（8）：798-801.
[23] 杜航，何文生，胡红兰，等.白术活性成分药理作用研究进展[J].江苏中医药，2022，54（5）：76-80.
[24] 牛淑睿，石芸，杨鑫，等.半枝莲化学成分的抗肿瘤作用研究进展[J].中国药房，2021，32（15）：1915-1920.
[25] 宋彤昕，贺明帅，吕佳霖，等.半枝莲化学成分及抗肿瘤作用研究进展[J].辽宁中医药大学学报，2020，22（10）：126-133.
[26] 蔡芸芸，高嵩，刘鲁明，等.半枝莲提取物通过Hippo/ YAP通路抑制胰腺癌PANC-1细胞的增殖、侵袭转移和成瘤能力的研究[J].中华中医药杂志，2017，32（7）：2947-2951.
[27] 徐亚晨，谢毅强，肖曼，等.基于网络药理学的半枝莲治疗胰腺癌的作用机制研究[J].中国医药导报，2020，17（29）：123-127.
[28] 李亚芹，瞿融.柴胡和黄芩配伍的研究进展[J].中国中医基础医学杂志，2018，24（2）：282-285.